Sign In
Buy ALGS
$4.23
-0.0900 (-2.08%)
At Close: Jul 31, 2026
- NIAID contract will support conducting nonclinical and clinical studies to advance ALG-097558 into future Phase 2/3 studies
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
07:30am, Thursday, 21'st Sep 2023
- Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024 - Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment exp
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
05:26pm, Wednesday, 24'th May 2023
SOUTH SAN FRANCISCO, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Lags Revenue Estimates
08:30pm, Thursday, 04'th May 2023
Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.84 per share a year ago.
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
04:05pm, Thursday, 27'th Apr 2023
SOUTH SAN FRANCISCO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on develop
SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
07:49pm, Thursday, 09'th Mar 2023
Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -4.08% and 26.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the
Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
07:00am, Friday, 10'th Feb 2023
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
4 Penny Stocks To Buy According To Analysts & Targets Over 600%
09:33am, Wednesday, 25'th Jan 2023
Analysts have put these on their list of penny stocks to buy. Do you agree?
4 Penny Stocks To Buy According To Insiders & Targets Up To 347%
09:29am, Thursday, 19'th Jan 2023
Penny stocks to buy according to analysts. The post 4 Penny Stocks To Buy According To Insiders & Targets Up To 347% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.co
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
04:15pm, Wednesday, 19'th Oct 2022
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel thera
Aligos' pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023 Aligos' pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2
Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference
04:05pm, Monday, 23'rd May 2022
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u
